Humacyte Ebit Per Revenue from 2010 to 2024
| HUMA Stock | USD 4.52 0.12 2.73% |
Ebit Per Revenue | First Reported 2010-12-31 | Previous Quarter (62.15) | Current Value (65.26) | Quarterly Volatility 22.0122811 |
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
Humacyte | Ebit Per Revenue |
Latest Humacyte's Ebit Per Revenue Growth Pattern
Below is the plot of the Ebit Per Revenue of Humacyte over the last few years. It is Humacyte's Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
| Ebit Per Revenue | 10 Years Trend |
|
Ebit Per Revenue |
| Timeline |
Humacyte Ebit Per Revenue Regression Statistics
| Arithmetic Mean | (28.51) | |
| Coefficient Of Variation | (77.22) | |
| Mean Deviation | 19.54 | |
| Median | (13.85) | |
| Standard Deviation | 22.01 | |
| Sample Variance | 484.54 | |
| Range | 51.4098 | |
| R-Value | (0.83) | |
| Mean Square Error | 164.24 | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | (4.07) | |
| Total Sum of Squares | 6,784 |
Humacyte Ebit Per Revenue History
About Humacyte Financial Statements
Humacyte stakeholders use historical fundamental indicators, such as Humacyte's Ebit Per Revenue, to determine how well the company is positioned to perform in the future. Although Humacyte investors may analyze each financial statement separately, they are all interrelated. For example, changes in Humacyte's assets and liabilities are reflected in the revenues and expenses on Humacyte's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Ebit Per Revenue | (62.15) | (65.26) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out the analysis of Humacyte Correlation against competitors. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Quarterly Revenue Growth (1.00) | Return On Assets (0.53) | Return On Equity (8.51) |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.